reported the results of A2AR inhibitor CPI-444 phase I trial NCT03454451 in 68 patients with RCC (81), 33 of which received CPI-444 alone and 35 received both CPI-444 and anti-PD-L1. Here, CD274 is linked to renal cell carcinoma.